96-Well Chromatin Immunoprecipitation (ChIP) Assay
Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation (ChIP) assay technology.
Developments in the field of epigenetics are rapidly expanding as researchers elucidate the principles governing gene regulation through the in vivo dynamic binding of proteins to DNA. Key to this is the need to analyse large numbers of high and low abundant regulatory mechanisms to systematically map protein-DNA interactions following pathogen/disease stimulus.
Chromatin immunoprecipitation (ChIP) assays are used to study these associations and have been historically limited to large sample numbers, onerous washing steps resulting in valuable sample losses and low signal to noise coupled with poor reproducibility. This new application note details the use of Chromatrap 96 Pro-A, a 96-well plate, each well of which contains a solid phase rigid porous polymer, BioVyon, to which Protein A is chemically bound, allowing up to 96 ChIP assays to be run in parallel on the same plate.
To determine ease of use, experimental design flexibility and reproducibility in screening multiple epigenetic targets with Chromatrap 96, the binding efficiency and occupancy of common epigenetic marks (H3, H4, H3K4me3 and RNA pol II) on three gene targets of interest (GAPDH, beta-globin, and PABPC1) in three human chromatin samples (HepG2, HeLa and K562) were performed simultaneously on the 96-well plate and analysed using qPCR. The application note describes in detail the analytical methodology, data interpretation and statistical analysis, as well as the benefits of using the new Chromatrap 96 high throughput ChIP assay plate, which include multiple target screening, flexible experimental design, robust reproducibility, high data quality and automated liquid handling potential.
To download a copy of this new application note, click here.
For further information or to discuss your application with technical product specialists please contact Porvair Sciences on +44 1372 824 290 / [email protected]
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...